Cagrilintide: The Long-Acting Amylin Analog

Most attention on the GLP-1 / GIP receptor axis overshadows a complementary pathway — amylin signaling — that has its own substantial research history. Cagrilintide is the long-acting amylin analog at the center of recent combination-research literature.

What amylin does

Amylin (also called Islet Amyloid Polypeptide, IAPP) is co-secreted with insulin from pancreatic beta cells. In published physiology research, amylin:

• Slows gastric emptying
• Suppresses postprandial glucagon secretion
• Acts on central satiety pathways through amylin-receptor signaling in the area postrema and hypothalamus

The mechanism of action complements incretin signaling rather than duplicating it. Where GLP-1 acts strongly on pancreatic beta cells, amylin acts strongly on central satiety and gastric-emptying signals. The two pathways together cover a broader functional surface than either alone.

Why cagrilintide, specifically

Native amylin has practical issues for research: short half-life, tendency to aggregate, and limited solubility. Cagrilintide is an engineered analog with structural modifications that address each:

• Substitutions at amyloid-prone residues to prevent aggregation
• Fatty-acid acylation (similar to semaglutide and tirzepatide) for albumin binding and extended half-life
• Suitable for weekly administration in research protocols

In the published literature, cagrilintide is the canonical amylin reference compound for combination work with tirzepatide or semaglutide.

Half-life and pharmacology

Plasma half-life in humans is approximately one week — enabling weekly administration in clinical research. Receptor activity is on the amylin receptor complex (calcitonin receptor + RAMP-1/2/3 accessory proteins).

Research contexts

Cagrilintide has been studied in:

• Combination with semaglutide (“CagriSema”) — clinical trials reporting additive metabolic effects beyond semaglutide alone
• Combination with tirzepatide in preclinical and early-clinical research
• Stand-alone weight-research clinical trials

Sourcing notes

Reference-grade cagrilintide should ship with HPLC purity >98%, mass-spec confirmation of the conjugated structure (the fatty-acid linker complicates the mass-spec interpretation slightly — look for clear notes on the COA), and counter-ion identity. The peptide is moderately stable; lyophilized storage at -20°C is standard.

For more on the incretin pair, see Tirzepatide: The Dual Receptor Mechanism Explained.